Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cannabis oil · 1 trial · 1 indication
To compare CBD, THC their and metabolites blood levels before and after intervention
To characterize the effect of medical cannabis treatment on the attention span using Conners teacher questionnaires. Significant change is defined as a change of 10% in questionnaire score between baseline and 6 months.
To examine the effect of cannabis treatment on cognitive level using part of Wechsler test. Significant change is defined as a change of 10% in questionnaire score between baseline and 6 months.
To compare efficacy of medical cannabis products with the same CBD: THC ratio in terms of communication skills using ADOS test. Significant change is defined as a change of 10% in raw questionnaire score between baseline and 6 months.
To examine the effect of cannabis treatment on adaptive behavior as per ADOS test. Significant change is defined as a change of 10% in raw questionnaire score between baseline and 6 months.
To examine the effect of cannabis treatment on violent behavior as per specific trial-designed questionnaire. Significant change is defined as a change of 10% in questionnaire score between baseline and 6 months.
| Arm | Type | Description |
|---|---|---|
| Seach CBD:THC 20:1 cannabis oil | ACTIVE_COMPARATOR | cannabis oil containing CBD:THC ratio of 20:1. plant material is grown by Seach LTD and oil manufactured by Nextar Pharma LTD. |
| Candoc CBD:THC 20:1 cannabis oil | ACTIVE_COMPARATOR | cannabis oil containing CBD:THC ratio of 20:1. plant material is grown by Candoc LTD and oil manufactured by Panaxia LTD. |
| Name | Type | Description |
|---|---|---|
| Cannabis oil | DRUG | Cannabis oil 20:1 CBD:THC ratio |
Inclusion Criteria * diagnosed with ASD by DSM * IQ below 70. The investigator can include patients with IQ above 70 if they have significant ASD or comorbid symptoms. * With significant behavior problems in for at least 6 months before recruitment Exclusion Criteria: * Epilepsy with clinical sym...
Top 3 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 3 | PHASE3 | Xanomeline and trospium chloride, KarX-EC |
| Definium Therapeutics, Inc. | DFTX | 1 | PHASE2 | DT402 |
| MapLight Therapeutics, Inc. | MPLT | 1 | PHASE2 | ML-004 |